MedTrace Logo

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

NCT00004036 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase I trial to study the effectiveness of amifostine plus combination chemotherapy in treating patients with advanced cancer.

Conditions

  • Chronic Myeloproliferative Disorders
  • Drug/Agent Toxicity by Tissue/Organ
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
  • Precancerous Condition
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

sargramostim

DRUG

amifostine trihydrate

DRUG

carboplatin

DRUG

cyclophosphamide

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • George Thomas Budd, MD · The Cleveland Clinic

Study Design

Purpose
SUPPORTIVE_CARE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004036 on ClinicalTrials.gov